Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiovascular Warning Boosts Profile For OTC NSAID Label Changes

This article was originally published in The Tan Sheet

Executive Summary

FDA more commonly requires similar changes for prescription drug labels based on emerging science on potential risks, but for non-aspirin NSAID label changes CDER also will contact OTC firms and advise them of changes needed to cardiovascular risk warnings on their product labels. “It doesn’t happen on quite the scale that we’re dealing with here and with the nature of these products,” says attorney Frederick Stearns.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS107784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel